Fourpath Capital Management LLC Increases Stock Position in Amgen Inc. (NASDAQ:AMGN)

Fourpath Capital Management LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 29.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,997 shares of the medical research company’s stock after acquiring an additional 679 shares during the quarter. Fourpath Capital Management LLC’s holdings in Amgen were worth $781,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Optas LLC lifted its position in Amgen by 15.6% in the 4th quarter. Optas LLC now owns 1,180 shares of the medical research company’s stock valued at $308,000 after acquiring an additional 159 shares in the last quarter. Hodges Capital Management Inc. lifted its holdings in shares of Amgen by 18.8% during the fourth quarter. Hodges Capital Management Inc. now owns 18,621 shares of the medical research company’s stock valued at $4,853,000 after purchasing an additional 2,949 shares in the last quarter. Rice Partnership LLC purchased a new stake in shares of Amgen during the fourth quarter valued at $303,000. Catalina Capital Group LLC increased its holdings in Amgen by 4.1% in the 4th quarter. Catalina Capital Group LLC now owns 2,425 shares of the medical research company’s stock worth $632,000 after buying an additional 95 shares in the last quarter. Finally, JB Capital LLC raised its position in Amgen by 4.6% in the 4th quarter. JB Capital LLC now owns 12,068 shares of the medical research company’s stock worth $3,146,000 after buying an additional 528 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $288.87 on Tuesday. The firm has a market cap of $155.28 billion, a price-to-earnings ratio of 36.99, a P/E/G ratio of 2.87 and a beta of 0.56. The firm has a fifty day moving average price of $271.06 and a 200 day moving average price of $304.11. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.30%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 115.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AMGN. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Bank of America reaffirmed an “underperform” rating and issued a $256.00 target price on shares of Amgen in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Wells Fargo & Company dropped their price target on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.